Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Seattle Genetics Inc (NASDAQ:SGEN)

54.01
Delayed Data
As of Sep 30
 +0.72 / +1.35%
Today’s Change
26.02
Today|||52-Week Range
57.23
+20.34%
Year-to-Date
3 Biotechs That Could Be M&A Targets
Sep 24 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close53.29
Today’s open53.47
Day’s range52.13 - 54.27
Volume786,242
Average volume (3 months)784,845
Market cap$7.6B
Dividend yield--
Data as of 3:59pm ET, 09/30/2016

Growth & Valuation

Earnings growth (last year)-50.00%
Earnings growth (this year)-7.77%
Earnings growth (next 5 years)-28.70%
Revenue growth (last year)+17.45%
P/E ratioNM
Price/Sales17.21
Price/Book11.00

Competitors

 Today’s
change
Today’s
% change
MNKMallinckrodt Plc+0.79+1.15%
JAZZJazz Pharmaceuticals...-1.53-1.24%
RDYDr.Reddy's Laborator...+0.18+0.39%
ALKSAlkermes Plc+0.32+0.69%
Data as of 4:04pm ET, 09/30/2016

Financials

Next reporting dateOctober 27, 2016
EPS forecast (this quarter)-$0.29
Annual revenue (last year)$336.8M
Annual profit (last year)-$120.5M
Net profit margin-35.77%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Clay B. Siegall
Chief Operating Officer
Eric L. Dobmeier
Corporate headquarters
Bothell, Washington

Forecasts

Search for Jobs